News
Ultragenyx Canada announces Health Canada approval of Crysvita for the treatment of tumour induced osteomalacia in adults.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, announced that Crysvita (burosumab injection) has been approved by Health Canada for the treatment of Tumour Induced Osteomalacia (TIO) in adults.
Crysvita is also approved for the treatment of X-Linked Hypophosphatemia.
TIO is a rare disease that is characterized by the development of tumours that cause weakened and softened bones. The tumours associated with TIO release a protein known as fibroblast growth factor 23 (FGF23) that lowers phosphate levels.
Condition: Tumor-Induced Osteomalacia
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
4 mins